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Ethyl-3,4-Dihydroxybenzoate with a Dual Function
of Induction of Osteogenic Differentiation and Inhibition
of Osteoclast Differentiation for Bone Tissue Engineering
Byeong-Ju Kwon, MS,1,2 Mi Hee Lee, PhD,1,2 Min-Ah Koo, MS,1,2 Jae-Jin Han, MS,3 and Jong-Chul Park, PhD1,2
The current approach in biomaterial design of bone implants is to induce in situ regeneration of bone tissue, thus
improving integration of the implants and reducing their failure. Therefore, ethyl-3,4-dihydroxybenzoate (EDHB),
which stimulates differentiation of osteoblasts and the resultant bone formation, should be studied. In this study,
the osteoinductive ability of EDHB in preosteoblasts and human mesenchymal stem cells was examined. EDHB
for future use in bone tissue engineering was evaluated by examination of early markers of differentiation (such as
alkaline phosphatase [ALP] activity and collagen type I expression) and late markers of osteoblast differentiation
(bone nodule formation). As bone remodeling and implant osteointegration depend not only on osteoblast re-
sponse but also on interaction of the biomaterial with bone-resorbing osteoclasts, differentiation of osteoclasts in
response to the compounds was also observed. For in vivo study, alginate gel comprised of EDHB and cells was
transplanted into the back subcutis of mice. Our results show that EDHB might have beneficial effects through
regulation of both osteoblast and osteoclast differentiation. Therefore, we suggest that EDHB could be a strong
candidate for dual regulation to increase osteoblast differentiation and decrease osteoclast differentiation.
Introduction
One of the main reasons bone implants fail is theirinability to induce osteoinduction, osteoconduction, or
the growth of bone tissue into the structure of graft. Therefore,
a new approach in biomaterial design is to create materials
that can induce in situ regeneration of bone. To stimulate local
bone tissue repair, new composites combining materials and
growth factors have recently been studied.1 In particular, the
ability of bone morphogenetic proteins to induce ectopic bone
formation has been discovered, and these proteins are con-
sidered promising therapeutics for bone tissue engineering.
However, recombinant proteins are, in general, less active than
their natural forms and require very high doses to be effective.
Other problems include their instability, short lifetime in the
body, high production cost, and difficult handling.2,3 Natural
compounds may be new possible candidates. Natural com-
pounds, such as antioxidants (e.g., epigallocatechin-3-gallate
derived from green tea) and other flavonoids (e.g., resver-
atrol and quercetin), induce differentiation of mesenchymal
stem cells (MSCs) to osteoblasts and enhance formation of
bone nodules.4–7 Additionally, histone deacetylase inhibi-
tors, such as valproic acid, trichostatin A, and sodium bu-
tyrate, alter transcription of genes related to osteogenic
differentiation by modifying chromatin structure and may
also be promising candidates.8,9
Ethyl-3,4-dihydroxybenzoate (EDHB) is a component of
the Rubus coreanus extract (Fig. 1), and the extract has
recently been shown to have a bone protecting-effect on
postmenopausal osteoporosis in ovariectomized rats.10
EDHB reduces collagen production in keloid fibroblasts11
and smooth muscle cells,12 and it inhibits myoblast differ-
entiation.13 Also, EDHB regulates heme oxygenase-1 mRNA
expression through hypoxia-inducible factor-1a-independent
mechanisms14; however, the dual function of EDHB of in-
ducing osteoblastic differentiation and inhibiting osteoclast
differentiation has not been previously evaluated and war-
rants further evaluation.15–17
Alginates have proven to be a biodegradable delivery
vehicle for tissue engineering application.18 They have fa-
vorable properties, such as good biocompatibility, a high
porosity, and interconnected porous structures for nutrient
and oxygen diffusion.19 The most common method of in-
corporating bioactive molecules or cells into alginate ma-
trices is via extrusion, in which an alginate suspension is
extruded through a needle to form droplets that fall into a
solution that contains divalent cations, causing alginate
cross-linking.20
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During the bone regeneration process, progenitor cells
play a role in receiving multiple signals, particularly from
proteins in extracellular matrix (ECM). Following these
signals, the cells initiate chemotaxis to the site of injury and
are subsequently differentiated to mature osteoblasts. This is
followed by secretion of ECM proteins and bone minerali-
zation.21 Therefore, a successful bioactive compound can-
didate for use in bone tissue engineering should be able to
stimulate and enhance the above-mentioned processes, and
we have analyzed them in the present study.
When bone integrity is damaged, under normal circum-
stances, MSCs play an important role in bone healing.
MSCs are multipotent cells of mesodermal origin, capable
of differentiating into osteoblasts, chondrocytes, adipocytes,
tenocytes, and myoblasts.22–27 These cells are identified as
marrow stromal cells because they are relatively abundant in
the bone marrow, which is their typical source. Apart from
bone marrow, they are found in the endosteum of the tra-
becular bone and in the periosteum.28 Limited sources of
MSCs include fat tissue, funicle blood, muscle, and synovial
membrane.29,30 MSCs are found in small quantities in pe-
ripheral blood and other tissues31 and have been isolated
from the liver, brain, and pancreas.32
Successful bone remodeling should be balanced between
bone formation and bone resorption. Upon implantation,
biomaterial interacts with both osteoblasts and osteoclasts.
Bone mass is controlled by continuous bone remodeling
through bone formation and bone resorption of osteoclasts.
Abnormalities in bone remodeling can produce a variety of
bone-decreasing disorders such as osteoporosis, hypercal-
cemia, rheumatoid arthritis, tumor metastasis into bone, and
periodontitis.33
The purpose of this study was to evaluate the os-
teoinductive effect of EDHB on preosteoblasts and human
MSCs (hMSCs). Using preosteoblast cells, the ability of the
EDHB to induce osteogenic differentiation and bone for-
mation was examined by studying both early and late
markers of differentiation, inducing matrix mineralization,
and analyzing bone nodule formation. Also, the effect of
EDHB on osteoclast differentiation was evaluated. Finally,
the osteoinductive effect of EDHB was evaluated in vivo.
Materials and Methods
Cell culture and materials
RAW264.7 mouse monocyte cells (ATCC) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Wel-
GENE) containing 4.0mM l-glutamine, 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, 1.0mM sodium pyruvate, 10%
fetal bovine serum (FBS), and 1% antibiotic-antimycotic
solution at 37C in a humidified atmosphere of 5% CO2.
MC3T3-E1 mouse preosteoblast cells (Riken Cell Bank)
were maintained in minimum essential medium a-modification
(a-MEM; WelGENE) without ascorbic acid and supplemented
with 10% FBS and 1% antibiotic-antimycotic solution.
hMSCs (Lonza) were maintained in MSC basal media
(Lonza) supplemented with MSC growth medium Single-
Quots Kit (Lonza). Osteogenic media was composed of
dexamethasone (10 nM), beta-glycerolphosphate (10mM),
and ascorbic acid (50 mg/mL).
EDHB was kindly supplied by CellSafe. The compound
was dissolved in ethanol, followed by filtering with syringe.
Sodium alginate was purchased from Sigma.
Osteoclast differentiation and tartrate-resistant
acid phosphatase assay
RAW264.7 is a murine monocyte cell line that can be
induced to differentiate into osteoclast-like cells by treat-
ment with receptor activator of nuclear factor-B ligand
(RANKL).34 RAW264.7 cells were seeded at 2.5 · 103 cells/
cm2 and incubated with RANKL (50 ng/mL) for 6 days to
obtain osteoclasts. Inhibition of differentiation was exam-
ined by co-treatment with the EDHB at 1, 2, and 4 mg/mL.
Mature osteoclasts were visualized by tartrate-resistant acid
phosphatase (TRAP) staining using the leukocyte acid
phosphatase kit (Sigma), according to manufacturer’s in-
structions. Multinucleated, TRAP-positive cells were coun-
ted under inverted phase-contrast microscope (IX-50;
Olympus), and multinucleated cells containing three or
more nuclei were scored as osteoclasts.
For measuring TRAP activity, multinucleated osteoclasts
were fixed with 10% formalin for 10min, followed by 95%
ethanol for 1min. The cells were incubated with 100mL of
citrate buffer (50mM, pH 4.6) containing 10mM sodium
tartrate and 5mM r-nitrophenylphosphate (pNPP; Sigma)
for 1 h. The reaction was stopped by adding 0.1N NaOH.
The absorbance of the resulting solution was measured us-
ing an ELISA reader (Spectra MAX3340; Molecular De-
vices Corp.) at a wavelength of 410 nm.
Alkaline phosphatase assay
To determine alkaline phosphatase (ALP) activity, MC3T3-
E1 cells were seeded at an initial density of 7· 103 cells/cm2.
Osteogenic media was supplemented after 24 h incubation and
exchanged every 3 days. The cells were cultured in the pres-
ence or absence of EDHB at 5mg/mL. At specific culture times
(i.e., 3, 7, and 10 days after seeding), the cells were rinsed with
phosphate-buffered saline (PBS) and lysed with 1% Triton X-
100 in Tris/NaHCO3 buffer (12.5mM each, pH 6.8). ALP
activity in the cell lysate was determined by a colorimetric
assay using phosphatase substrate (pNPP; Sigma), which is
converted to a yellow, soluble end product. Cell lysates were
mixed with 10mM pNPP solution in glycine buffer (0.1M
glycine with 1mM MgCl2 and 1mM ZnCl2, pH 10.4) and
incubated at 37C for 30min. The absorbance was measured at
405nm. At the same time, cell lysate protein concentrations
were determined by bicinchoninic acid assay (Pierce Bio-
technology), according to the manufacturer’s protocol.
Collagen assay
Collagen is specifically bound by Sirius Red stain, which
was used as described previously.35 Briefly, collagen deposited
FIG. 1. Chemical structure of ethyl-3,4-dihydroxybenzoate
(EDHB).
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in the ECM on days 7, 10, and 14 after treatment with EDHB
(5mg/mL) was visualized with 0.1% Sirius Red stain (Sircol;
Biocolor Ltd.). The cells were fixed with 3% paraformalde-
hyde and stained with Sirius Red solution for 30min. For
quantitative analysis, the collagen-bound stain was eluted by
washing with 0.1M NaOH, and its absorbance at 540nm was
measured using an ELISA reader.
Mineralization test: Alizarin Red staining
Mineralization of collagenous matrix was observed by
Alizarin Red S (ARS) staining of calcium deposits. MC3T3-
E1 was cultured in the presence or absence of EDHB (5mg/
mL), and mineralization was detected after 3, 4, and 5 weeks
of culture. Cell monolayers were rinsed with PBS, fixed in
70% ethanol, and stained with a 40mM solution of ARS (pH
4.2) for 30min. After washing, the plate was photographed.
For quantitative analysis, the staining was extracted by in-
cubation in 1mL of 10% (w/v) cethylpyridinium chloride
(Sigma) with shaking for 30min. Optical density of the
extracted stain was read at 570 nm.
Western blot analysis
To conduct western blot analysis of the runt-related
transcription factor 2 (Runx2) expression, MC3T3-E1 cells
were seeded at an initial density of 2 · 105 cells/well in six-
well plates, and incubated for 5 days in the presence or
absence of EDHB at 1 and 5 mg/mL. On given days, the cells
were rinsed with ice-cold PBS and lysed with ice-cold RIPA
buffer. The cell lysate was collected and centrifuged at
14,000 g for 15min at 4C. Protein concentrations in the
solution were determined by DC Bio-Rad assay according to
the manufacturer’s protocol (BioRad Laboratories, Inc.).
Protein samples were separated using 12.5% SDS-PAGE
gels and then transferred to PVDF membranes. The mem-
branes were blocked with blocking buffer (5% nonfat dry
milk and 1% Tween-20 in 20mM TBS, pH 7.6) for 1 h at
room temperature, and then probed overnight at 4C with
rabbit monoclonal anti-Runx2 antibody (1:2000 dilution; Cell
Signaling Technology) or mouse monoclonal anti-GAPDH
antibody (1:5000 dilution; Chemicon International). Finally,
the membranes were incubated with secondary antibody (i.e.,
anti-mouse IgG [1:2000], anti-rabbit IgG [1:2000] from Santa
Cruz Biotechnology, Inc.), horseradish peroxidase-conjugated.
Protein expression was detected by ECL (Amersham Bio-
sciences). Densitometry of bands was evaluated using Image
J software.
hMSC culture in an alginate bead three-dimensional
culture system
hMSCs were suspended at 1 · 106 cells/mL in sterile 4%
(w/v) sodium alginate solution. The cell-gel solution was
dropped through a 20-gauge needle into a stirred solution of
100mM calcium chloride (Sigma). Alginate beads were
allowed to stabilize for 10min followed by culture in a
HARV bioreactor (Synthecon, Inc.) for 21 days. The vessel
was rotated at 20 rpm. The control media consisted of
dexamethasone (10 nM), beta-glycerolphosphate (10mM),
ascorbic acid (50mg/mL), and CaCl2 (200mg/L). Ethanol
alone was used as a control solution because EDHB was
dissolved in ethanol. The EDHB media was treated with
EDHB (10 mg/mL) that was exchanged every 2 days.
In vivo study: subcutaneous injection of nude mouse
with alginate-EDHB beads
Six-week-old Balb/c nude mice were purchased from
Orient Bio. All animal experiments were performed in ac-
cordance with the Korean Food and Drug Administration
(KFDA) guidelines. Protocols were reviewed and approved
by the Institutional Animal Care and Use Committee (IA-
CUC) of the Yonsei Laboratory Animal Research Center
(YLARC) (Permit No. 2011-0107). All mice were main-
tained in the specific pathogen-free facility of the YLARC.
A total volume 200mL of alginate gel with cells was sub-
cutaneously transplanted into the back of the mice. The mice
were divided into the following groups: the control group
was transplanted with alginate gel with hMSCs; the second
group received alginate gel with dexamethasone at (10 nM)
and hMSCs; and the third group received alginate gel with
EDHB (5 mg/bead, 50 mg/bead) and hMSCs. The animals
were sacrificed at 5 or 8 weeks following transplantations,
and the transplanted site was isolated for histological and
immunohistochemical examinations.
In vitro release test of EDHB from EDHB-loaded
alginate bead
To evaluate the in vitro release profiles of EDHB from
EDHB (25mg/mL)/alginate beads and EDHB (250 mg/mL)/
alginate beads, each sample was immersed in PBS buffer
(pH 7.4) at 37C. At predetermined time intervals of 1, 2, 3,
4, 5, 24, 72, 120, and 168 h, the supernatant was collected
and replaced with fresh PBS solution. The amount of EDHB
released in the collected solution was determined spectro-
photometrically at a wavelength of 214 nm.
Histology and immunohistochemistry
The injection site was completely excised and processed
for classical histology. hMSCs seeded in the alginate bead
were fixed in neutral buffered formaldehyde solution. Spe-
cimens were cut into 4-mm-thick sections, after which the
nucleus and cytoplasm were stained with hematoxylin and
eosin (H&E). For von Kossa staining, sectioned alginate gel
slides were incubated in 1% silver nitrate solution under UV
lamp for 1 h. The reaction was stopped by incubation in 5%
sodium thiosulfate solution for 5min. As mentioned above,
ARS staining was also carried out.
For immunohistochemical analysis, unstained paraffin
section slides were rehydrated with a series of ethanol. In
sequence, these slides were exposed to 0.3% hydrogen
peroxide, incubated in citrate buffer (pH 6.0) at 95C for
20min, and blocked in 1% BSA solution for 10min. The
slides were then incubated overnight at 4C with primary
antibodies to collagen type I (1:500 dilution; R&D System)
or osteocalcin (1:20 dilution; Abcam) and staining with
LSAB + System-HRP kit (Dako) following the manufactur-
er’s protocol. Sections were dehydrated and mounted. The
samples were observed using an optical microscopy (BH-2;
Olympus).
Statistical analysis
All results are expressed as mean – standard deviation for
the three determinations and analyzed by Student’s t-test.
Statistical significance was defined as p < 0.05.
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FIG. 2. EDHB decreased
osteoclast formation. (a)
RAW264.7 cells were co-
treated with receptor activator
of nuclear factor-B ligand
(RANKL) and EDHB (1–4mg/
mL) for 6 days. (b)Mature
multinucleatedosteoclastswere
counted following staining to
detect tartrate-resistant acid
phosphatase (TRAP)-positive
multinucleated cells. (c) EDHB
treatment significantly de-
creased TRAP activity com-
pared with treatment with
RANKL alone (* p<0.05).
Color images available online
at www.liebertpub.com/tea
FIG. 3. Osteogenic differ-
entiation of MC3T3-E1 cells
cultured in vitro. Analysis of
alkaline phosphatase (ALP)
activity (a), collagen assay
(b), Alizarin Red S (ARS)
staining (c), and western blot
analysis for the runt-related
transcription factor 2
(Runx2) (d). Each error bar
represents the mean – stan-
dard deviation (SD) (n= 3).
*Statistically significant dif-
ferences ( p < 0.05). Color
images available online at
www.liebertpub.com/tea
2978 KWON ET AL.
Results
Inhibitory effect of EDHB on osteoclast differentiation
To evaluate the effect of EDHB on osteoclast differentia-
tion, RAW264.7 cells were cultured in the presence of
RANKL with EDHB (Fig. 2a). Osteoclast differentiation was
confirmed by counting large multinucleate osteoclasts fol-
lowing 6 days of culture in the presence or absence of EDHB
(Fig. 2b). RAW264.7 cells treated with RANKL showed
multinucleated osteoclasts after 6 days of treatment. The
number of multinucleated osteoclasts was decreased in the
EDHB-treated group, but it was not significantly different.
The effect was further determined by quantification of
TRAP activity (Fig. 2c). EDHB at low concentrations led to
an increase in TRAP activity. EDHB induced a significant
decrease in osteoclast differentiation, starting at concentra-
tion of 2 mg/mL. EDHB at concentration of 2 and 4 mg/mL
steadily reduced TRAP activity by 54% and 77%, respec-
tively, in comparison with RANKL-only treated cells. These
results suggest that osteoclast formation significantly cor-
related with the amount of EDHB in the culture medium and
EDHB has an inhibitory effect of osteoclast formation. Also,
EDHB induced a biphasic effect on osteoclast differentia-
tion, inducing differentiation at lower concentrations and
inhibiting differentiation at higher concentrations.
Osteoblast differentiation effect of EDHB
on MC3T3-E1
To determine whether osteoblastic differentiation was
stimulated by EDHB treatment, preosteoblasts were treated
with EDHB (5mg/mL). ALP activity as an early marker of
osteoblast differentiation was examined. This activity was
evaluated over 10 days of culture of MC3T3-E1 in control
media or osteogenic media with or without EDHB (Fig. 3a).
The ALP activity of cells in osteogenic media only and
EDHB-treated cells continuously increased even after day 7
but did not reach their peak until the end of the assay (day 10).
The ALP activity of treated EDHB was increased significantly
for 10 days, and the increase over this time period was more
than twofolds compared with cells in only osteogenic media.
Collagen assay was measured over 14 days as a middle
marker of osteoblast differentiation in MC3T3-E1 cells
stimulated by EDHB in osteogenic media (Fig. 3b). In
MC3T3-E1 cells treated with EDHB, collagen deposition
steadily increased up to day 14 when it was reached its peak.
Because type I collagen is the major matrix component of
bone and plays a critical role in mineralization, we compared
the quantity of collagen deposited by the EDHB-treated and
non-treated MC3T3-E1 cells. At days 7 and 10, the collagen
deposition was decreased by 37% and 31% respectively, in
the group of MC3T3-E1 treated with EDHB, compared with
cells treated with osteogenic media only. However, as shown
in Figure 3b, the quantity of collagen deposited in the ECM
was increased in the group of cells treated with EDHB on day
14 compared with cells treated with osteogenic media only.
To evaluate bone nodule formation, MC3T3-E1 cells
were cultured in osteogenic medium with EDHB (5 mg/mL)
FIG. 4. Histological im-
ages of alginate beads cul-
tured in a bioreactor for 21
days. (a, b) hematoxylin and
eosin (H&E) staining, (c, d)
von Kossa staining, and (e–f)
ARS staining. Color images
available online at www
.liebertpub.com/tea
FIG. 5. Accumulative release profiles of EDHB ((a) up to
5 h, (b) up to 168 h) from alginate beads. The error bars
represent mean – SD (n = 4).
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for 3, 4, or 5 weeks (Fig. 3c). The levels of bone nodule
formation were visualized by staining with ARS and quan-
tified by measuring the absorbance of the red dye eluted. As
shown in Figure 3c, the stained region of red indicates bone
nodule-like mineralized matrix accumulation. ARS staining
showed large mineralized areas (in red) in the presence of
EDHB, whereas little staining was visible in the untreated
group. Quantitatively, the amount of calcium deposition at 5
weeks was 34% higher in the EDHB-treated group com-
pared with the untreated group, and this difference was
statistically significant (*p < 0.05). Overall, MC3T3-E1 cells
treated with EDHB showed markedly increased calcification
of ECM compared with that in the non-treated cells.
We determined the expression of the bone-associated
transcription factor Runx2, which is essential for osteo-
genesis, especially for the development of osteoblasts.36
Quantitative analysis of this transcript in MC3T3-E1 cells
demonstrated a significant increase in Runx2 activity at day
5 compared with untreated cells (Fig. 3d).
These results indicate that EDHB may play a role in
the stimulatory effect on osteoblast differentiation in
preosteoblasts.
Histological analysis of hMSCs cultured in a bioreactor
in alginate bead
To evaluate the osteoinductive activity in a three-
dimensional (3D) dynamic culture system, hMSCs were
cultured in a HARV bioreactor for 21 days. hMSCs cultured
in a bioreactor with osteogenic media containing EDHB
showed more red or black color using ARS and von Kossa
staining methods, compared with the hMSCs cultured in
osteogenic media (control). H&E staining confirmed well-
formed 3D tissue formation within the alginate gel (Fig. 4).
In vitro EDHB release test
The release profiles obtained after the release of EDHB
from alginate beads are shown in Figure 5. The amount of
EDHB (25mg/mL) and EDHB (250 mg/mL) released on the
5 h was *48% and 35%, respectively (Fig. 5a). Over a
period of 168 h, 25 and 122mg/mL of EDHB was released
from the 25 mg/mL-EDHB in alginate beads and 250mg/mL-
EDHB in alginate beads, respectively (Fig. 5b). EDHB was
released from the alginate beads in a rapid burst over the
first 5 h followed by a phase of slower release.
FIG. 6. In vivo Balb/c nude
mice model for bone tissue
engineering. Histological
images of human mesenchy-
mal stem cells (hMSCs)
inserted in alginate beads
with different types calcium
deposition. H&E staining,
von Kossa staining, and ARS
staining (a) at 5 weeks after
implantation and (b) 8 weeks
after implantation. Color
images available online at
www.liebertpub.com/tea
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Histological/immunohistochemical analysis of implanted
alginate bead to study in vivo bone formation
To examine osteogenic differentiation, hMSCs inserted
into alginate beads containing dexamethasone or EDHB
were transplanted into Balb/c nude mice. H&E staining was
used to determine cell distribution and cell density (Fig. 6).
At 5 and 8 weeks following transplantation of hMSCs into
nude mice, alginate beads containing dexamethasone or
EDHB showed much denser cell distributions. However,
alginate bead containing only hMSCs showed smaller
amounts of cells.
ARS and von Kossa staining of hMSCs embedded onto
alginate beads containing dexamethasone or EDHB were
analyzed to evaluate the calcium levels produced in vivo.
Osteoblast cells converted from hMSCs that were embedded
into alginate beads containing dexamethasone or EDHB had
increased calcium that was secreted and accumulated by
hMSCs. EDHB induced a significant increase in the mineral
deposition area in a dose-dependent manner. However, al-
ginate beads with only hMSCs did not affect calcium ac-
cumulation. Calcium accumulation by hMSCs showed that
EDHB enhanced calcium deposition through differentiation
of hMSCs into osteoblast cells. This result indicated that
hMSCs differentiated into osteoblasts that could produce
calcium and suggested that EDHB could help bone forma-
tion through increased osteoblast differentiation. EDHB-
enhanced bone formation may have dual functions in
regulating both osteoblasts and osteoclasts in vivo.
Collagen type I and osteocalcin were analyzed to deter-
mine whether hMSCs inserted into alginate gel differenti-
ated into bone cells in response to stimulation with EDHB
(Fig. 7). The expression of collagen type I was similar upon
treatment with either dexamethasone or EDHB (Fig. 7a). As
a middle marker, collagen type I is typically expressed
within 8 weeks, and its level of expression was not signifi-
cantly different from either dexamethasone or EDHB. In the
controls, osteocalcin staining was weak. On the other hand,
the increased level of osteocalcin we found indicates that the
implanted hMSCs differentiated into osteoblasts when
treated with dexamethasone or EDHB (Fig. 7b).
Discussion
In this study, we investigated whether EDHB inhibits
osteoclast differentiation and stimulates osteoblastic differ-
entiation in vitro and in vivo. We confirmed the os-
teoinductive effect of EDHB and analyzed the cell response.
Also, we demonstrated that EDHB caused an increase in the
calcification of the ECM in MC3T3-E1 cells without any
significant cytotoxic effects on the cells (Supplementary
Fig. S1; Supplementary Data are available online at www
.liebertpub.com/tea). The ability of EDHB to induce osteo-
genic differentiation was confirmed by increases in ALP
expression, collagen deposition, bone nodule formation,
Runx2 expression, and bone regeneration.
Bone is continuously destroyed and reformed in verte-
brates to maintain bone volume and calcium homeostasis.
Osteoblasts and osteoclasts are specialized cells responsible
for bone formation and resorption, respectively. Osteoblasts
produce bone matrix proteins, including type I collagen, the
most abundant extracellular protein of bone, and also cause
tissue mineralization.37 Osteoblasts, chondrocytes, myocytes,
and adipocytes are all derived from a common progenitor
called undifferentiated mesenchymal cells. During cell dif-
ferentiation, progenitor cells acquire specific phenotypes
under the control of their respective regulatory factors.38
In our in vitro study using RAW264.7 cells, we found that
EDHB at concentrations of 2 and 4 mg/mL dose-dependently
inhibited RANKL-induced osteoclast differentiation. The
FIG. 7. Immunohisto-
chemical analysis of alginate
beads 8 weeks following
implantation. (a) Images
showing collagen type I
(COL-I) in alginate beads
with hMSCs in the presence
of dexamethasone (10 nM) or
EDHB (5 mg/bead and 50 mg/
bead) 8 weeks following im-
plantation. (b) Images show-
ing osteocalcin (OCN) in
alginate beads with hMSCs
in the presence of dexa-
methasone (10 nM) or EDHB
(5 mg/bead and 50mg/bead) 8
weeks following implanta-
tion. Black rectangle boxes
indicate the enlarged photo-
graph of the images below.
Color images available on-
line at www.liebertpub
.com/tea
DUAL FUNCTION OF EDHB ON BONE DIFFERENTIATION 2981
total TRAP activity was most dramatically reduced with
EDHB treatment. This might be attributable to the presence
of TRAP-positive mononuclear cells in EDHB-treated cul-
tures. Therefore, we found that EDHB dose-dependently
suppressed the osteoclast differentiation and bone resorption
activity at an early stage of osteoclastogenesis in cultured
RAW264.7 cells. Also, we found that EDHB induced a bi-
phasic effect on osteoclast differentiation, inducing differen-
tiation at lower concentrations and inhibiting differentiation
at higher concentrations. Karst et al.39 reported that low-dose
TGF-b stimulation of spleen and marrow precursors cultured
with stromal support cells may be accounted for by regulation
of the RANKL/osteoprotegerin (OPG) expression ratio in
stromal cells. Accordingly, EDHB may be capable of stim-
ulating RANKL expression at any concentration.
Tissue engineering for bone repair has received consid-
erable attention in reconstructive surgery during the past
decade. The most common strategy to engineer bone is
performed using three components: a scaffold, growth fac-
tors, and MSCs. There are a number of reports of successful
bone formation achieved with a combination of these three
elements in animal experiments.40 However, there are only a
few reports of successful bone formation using an injectable
gel as a scaffold for the cells.41 In this study, the alginate gel
was completely resorbed without forming new bone when
the alginate gel contained only MSCs. We used calcium
alginate as carrier material for several reasons. First, algi-
nate is a biocompatible polysaccharide that is structurally
similar to the glycosaminoglycans present in cartilage.42–44
Also, alginate gelation properties allow gel formation di-
rectly on bone defects by the simple addition of a calcium
chloride solution. Thus, it is a fluid material that can fill the
shape of any defect and incorporate various bioactive agents
(e.g., proteins and growth factors).45–48 Alginate has been
extensively studied in cartilage tissue regeneration.
Osteoclast differentiation is regulated by many systemic
hormones and local cytokines (e.g., tumor necrosis factor-a,
interukin-1, interukin-6, parathyroid hormone, and macro-
phage colony-stimulating factor).49 Recently, a more direct
anabolic role of osteoclasts in stimulating bone formation has
been suggested, one in which osteoclasts secrete anabolic
growth factors that mediate osteoblast chemotaxis, prolifer-
ation, differentiation, and mineralization.50–53 However, the
mechanism of osteoclast-mediated bone formation is not
well understood. Cytokines and growth factors released
from osteoclasts may assist in maintaining a healthy bal-
ance between adipogenic and osteogenic differentiation.54
RANKL, a stimulator of osteoclast differentiation and ac-
tivity, and OPG, the inhibitor of osteoclastogenesis, are
differentially expressed during osteoblast development.55
Bone regeneration may be influenced by stimulating os-
teoblast differentiation and preventing osteoclast differentia-
tion. We suggest that EDHB could help bone remodeling by
stimulating osteoblast differentiation, while, at the same time,
preventing bone loss by inhibiting osteoclast differentiation.
Conclusions
In conclusion, this study examined the utility of EDHB to
increase osteoinductive activity and decrease bone resorp-
tion. We demonstrated that EDHB can be an effective bio-
active compound material and that it plays a role in inducing
osteoblast differentiation and inhibiting osteoclast differen-
tiation. We verified the osteoinductive activity through an-
imal testing. Therefore, EDHB is a strong candidate for dual
regulation of osteoblasts and osteoclasts in bone tissue en-
gineering. Our future objective is to further investigate the
mechanism of this dual regulation.
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